Since the first landmark report by Mackensen et al. in 2022 describing five refractory SLE patients achieving sustained remission after anti-CD19 CAR-T therapy [10], several studies and case series have expanded the evidence base [11–14]. This evidence concerns the gene CD19 and systemic lupus erythematosus.